Cardiovascular disease (CVD) is a health problem worldwide, and elevated cholesterol
levels are a key risk factor for the disease. Dysbiotic gut microbiota has been shown to be …

Although promising therapeutics are in the pipeline, bariatric surgery (also known as
metabolic surgery) remains our most effective strategy for the treatment of obesity and type 2 …

Alterations in the microbiome correlate with improved metabolism in patients following
bariatric surgery. While fecal microbiota transplantation (FMT) from obese patients into germ …

Given the increasing number of people living with obesity and related chronic metabolic
disease, precision nutrition approaches are required to increase the effectiveness of …

Diet-induced metabolic dysfunction-associated steatotic liver disease (MASLD) is a
prevalent metabolic disorder with limited effective interventions available. A novel approach …

Obesity is a heterogenous disease accompanied by a broad spectrum of cardiometabolic
risk profiles. Traditional paradigms for dietary weight management do not address biological …

Over the past 40 years, the prevalence of obesity has risen dramatically, reaching epidemic
proportions. By 2030 the number of people affected by obesity will reach 1.12 billion …

Combination therapies targeting multiple organs and metabolic pathways are promising
therapeutic options to combat obesity progression and/or its comorbidities. The alterations in …

The association between the physio-pathological variables of type 2 diabetes (T2D) and gut
microbiota composition suggests a new avenue to track the disease and improve the …

Diabetes mellitus is one of the major epidemics in the United States. It is heavily associated
with obesity and multiple metabolic derangements that lead to long term morbidity, mortality …